in vivo News and Research

RSS

Single-dose Israeli vaccine candidate protective against SARS-CoV-2

Now, a new Israeli study published on the preprint server bioRxiv in June 2020 reports a new recombinant vaccine expressing the S or spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be highly protective with a single dose in an animal model. This could be a gamechanger in the fight to contain the outbreak.

23 Jun 2020

Colombian corona hounds: SAR-CoV-2 detection by dogs

A new Colombian study published on the preprint server bioRxiv in June 2020 describes the use of trained dogs to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected humans by scent alone. This would allow uninfected people to work together safely, rescuing the economy without driving up medical costs.

23 Jun 2020

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.

22 Jun 2020

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

In a recent groundbreaking bioRxiv paper, Chinese researchers describe a novel approach towards coronavirus disease (COVID-19) vaccine design based on engineered human mesenchymal stem cells, with favorable and promising antibody response.

22 Jun 2020

Synthetic peptide could be an effective COVID-19 treatment and SARS-CoV-2 vaccine

Ligandal, one of the world’s leading genetic medicine companies, has modeled a synthetic peptide that could be an effective COVID-19 treatment and SARS-CoV-2 vaccine.

22 Jun 2020

Unexpected discovery helps explain fundamental mystery about how muscles work

Researchers at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association developed a mouse model that enables them to look inside a working muscle and identify the proteins that allow the sarcomere to contract, relax, communicate its energy needs, and adapt to exercise.

21 Jun 2020

Researchers find prothrombotic antibodies in patients with COVID-19

Even as the COVID-19 pandemic continues to spread across the world, researchers are still trying to understand the many ways in which it can manifest and its pathogenesis. A new report published on the preprint server medRxiv* in June 2020 shows that one possible mechanism of disease in COVID-19 is the production of antiphospholipid antibodies.

19 Jun 2020

AFFiRiS AG announces results of phase 1 trial with PD01A in Parkinson's

AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson's disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology.

18 Jun 2020

Lonza and CELLINK collaborate to advance complete 3D cell culture workflows

Lonza and the Swedish company CELLINK have partnered to offer a comprehensive 3-dimensional bioprinting solution designed to optimize and increase access to complete 3D cell culture workflows.

18 Jun 2020

Researchers call for caution of using CAR-T immunotherapy against AML

Acute myeloid leukemia is a hematological malignancy which incidence increases with age, that is biologically, phenotypically, and genetically very heterogeneous.

17 Jun 2020

Integrin-binding peptide ATN-161: Potential COVID-19 treatment

Now, a new study by researchers at Tulane University and published on the preprint server bioRxiv* in June 2020 reports the potential role of an integrin inhibitor ATN-161 to prevent ACE2-S protein binding.

17 Jun 2020

Mapping RNA sequences of therapeutic value in the SARS-CoV-2 genome

Now, in new research published on the preprint server bioRxiv European scientists have performed RNA structure probing to obtain a single-base resolution secondary structure map of the full SARS-CoV-2 coronavirus genome.

17 Jun 2020

Novel ACE2-antibody fusion molecules show anti-SARS-CoV-2 activity

Now, in a new study published on the preprint server, bioRxiv researchers in the U.S. investigated a soluble version of ACE2 for SARS-CoV-2 viral neutralization activity.

17 Jun 2020

Scientists isolate powerful SARS-CoV-2 -neutralizing antibodies from COVID-19 patients

A new study has shown that potent antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could help protect against COVID-19 infection. Preliminary results in animal studies have so far proven successful. The study titled, "Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model," was published in the latest issue of the journal Science.

17 Jun 2020

Exposure to certain e-cig cartridges may cause fatal lung damage

Researchers at the University of Rochester Medical Center, New York, have shown that long-term exposure to certain electronic nicotine delivery systems (ENDS) may cause lung toxicity and injury among vapers.

16 Jun 2020

Depression and anxiety symptoms linked to changes in the brain's opioid system

A new study conducted in Turku, Finland, reveals how symptoms indicating depression and anxiety are linked to brain function changes already in healthy individuals.

16 Jun 2020

First National Preclinical Imaging Centre established in Ireland to enhance medical research

A new National Preclinical Imaging Centre which will provide enhanced research data to inform new clinical trials that aim to improve patient outcomes, has been awarded funding of €3.4 million under the Science Foundation Ireland Research Infrastructure Programme.

16 Jun 2020

Accelerating the Diagnosis and Treatment of Cancer with Mass-Spectrometry Based Techniques

An interview with Livia Eberlin, Assistant Professor at the University of Texas at Austin, discussing the development of mass-spectrometry based techniques for cancer diagnosis and improved clinical outcomes.

From Pittcon 16 Jun 2020

Inhaled steroids reduce ACE2 expression in COPD lungs

A new study by scientists at Imperial College London, University of Newcastle and Prokarium, and published on the preprint server bioRxiv* in June 2020 examines the role played by inhaled corticosteroids (ICS) in the risk of acquisition of COVID-19 infection by COPD patients.

15 Jun 2020

Hydroxychloroquine ineffective in animal SARS-CoV-2 infection

A new study by scientists from the U.S and U.K. and published on the preprint server bioRxiv in June 2020 reports that there is no evidence of efficacy for the drug hydroxychloroquine (HCQ) against infection with SARS-CoV-2 in hamsters or macaque models. This finding does not support the current widespread prophylactic and therapeutic use of HCQ in COVID-19.

14 Jun 2020